Īslande - īslandiešu - LYFJASTOFNUN (Icelandic Medicines Agency)

tillotts pharma gmbh - budesonidum inn - hart hylki með breyttan losunarhraða - 3 mg

Īslande - īslandiešu - LYFJASTOFNUN (Icelandic Medicines Agency)

glaxosmithkline pharma a/s - lifrarbólgu b yfirborðsmótefnavaki - stungulyf, dreifa

Eiropas Savienība - īslandiešu - EMA (European Medicines Agency)

samsung bioepis nl b.v. - eculizumab - blóðrauði, ofsakláði - Ónæmisbælandi lyf - epysqli is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). evidence of clinical benefit is demonstrated in patients with haemolysis with clinical symptom(s) indicative of high disease activity, regardless of transfusion history.

Eiropas Savienība - īslandiešu - EMA (European Medicines Agency)

amgen technology (ireland) uc - eculizumab - blóðrauði, ofsakláði - Ónæmisbælandi lyf - bekemv is indicated in adults and children for the treatment of paroxysmal nocturnal haemoglobinuria (pnh). sönnunargögn klínískum gagn er sýnt í sjúklinga með haemolysis með klínískum einkenni(s) marks um hár sjúkdómur starfsemi, óháð blóðgjöf sögu (sjá kafla 5.

Eiropas Savienība - īslandiešu - EMA (European Medicines Agency)

janssen-cilag international n.v. - talquetamab - mergæxli - Æxlishemjandi lyf - talvey is indicated as monotherapy for the treatment of adult patients with relapsed and refractory multiple myeloma, who have received at least 3 prior therapies, including an immunomodulatory agent, a proteasome inhibitor, and an anti cd38 antibody and have demonstrated disease progression on the last therapy.

Eiropas Savienība - īslandiešu - EMA (European Medicines Agency)

almirall, s.a. - lebrikizumab - dermatitis, atópísk - aðrar húðsjúkdómar - ebglyss is indicated for the treatment of moderate-to-severe atopic dermatitis in adults and adolescents 12 years and older with a body weight of at least 40 kg who are candidates for systemic therapy.